Discontinued — last reported Q4 '25
Products & Services · Sales
Simponi — Sales
Over 4 years (FY 2021 to FY 2025), Simponi — Sales shows a downward trend with a -100.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ4 2025
Rolls up toTotal Revenue
How to read this metric
An increase in sales indicates strong market adoption and effective competitive positioning, while a decrease may signal patent expiration, increased competition from biosimilars, or a shift in clinical treatment guidelines.
Detailed definition
This metric represents the total annual revenue generated from the sale of the Simponi product line, a biologic therapy...
Peer comparison
Comparable to revenue metrics for specific biologic or specialty pharmaceutical products within the immunology portfolios of peer companies like AbbVie or Johnson & Johnson.
Metric ID:
mrk_segment_simponi_salesHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $404.00M | $406.00M | $412.00M | $372.00M | $362.00M | $346.00M | $332.00M | $360.00M | $360.00M | $358.00M | $342.00M | $368.00M | $344.00M | $378.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +0.5% | +1.5% | -9.7% | -2.7% | -4.4% | -4.0% | +8.4% | +0.0% | -0.6% | -4.5% | +7.6% | -6.5% | +9.9% | -100.0% | — | — | — | — |
| YoY Change | — | — | — | — | -10.4% | -14.8% | -19.4% | -3.2% | -0.6% | +3.5% | +3.0% | +2.2% | -4.4% | +5.6% | -100.0% | -100.0% | -100.0% | -100.0% | — |
Range$0.00 – $412.00M
CAGR-100.0%
Avg YoY Growth-31.3%
Median YoY Growth-7.4%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s simponi — sales?
- Merck & Co. (MRK) reported simponi — sales of $0.00 in Q4 2025.
- What is the long-term trend for Merck & Co.'s simponi — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s simponi — sales has grown at a -100.0% compound annual growth rate (CAGR), from $1.65B to $0.00.
- What does simponi — sales mean?
- The total annual revenue generated from sales of the Simponi pharmaceutical product.